



# OncoSil™

Intratumoural placement of  $^{32}\text{P}$  for locally advanced pancreatic cancer

**Targeted Approach • Positive Impact**

*Nigel Lange, 20 November 2025*



This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website [www.oncosil.com](http://www.oncosil.com) for further information.

## **Not an Offer for Securities**

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction.

This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a "Prospectus" or a "Disclosure Document" (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this presentation should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of law. Please refer to the international offer restrictions section of this presentation.

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or in any jurisdiction in which such offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

## **Forward-Looking Statements**

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved.

In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

## **Disclaimer**

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents.

The information contained in this presentation is current as at 20 November 2025.

# Corporate Overview




## OncoSil Medical | 13 November 2025

GICS:	Health Care – Pharmaceuticals, Biotechnology & Life Sciences (Life Sciences Tools & Services)
ASX code:	OSL
Market cap:	\$24.7 million
Shares on Issue:	18.83 million
Share price:	\$1.31 (as at 13-Nov-25)
52-week high:	\$3.60
52-week low:	\$0.80
Average daily volume:	31,654
Free float:	66.2%
Cash on Hand (30-Sep-25)	\$5.92 million

## OncoSil Medical Major Shareholders | 13 November 2025

Washington H. Soul Pattinson (Pengana Capital Group Limited)	18.18%
State Street Australia Ltd (Australian Ethical Investment Limited)	6.93%
<b>TOP 20</b>	<b>54.0%</b>

### Share Price Performance



Volume LHS    Share Price (\$) RHS

# • About OncoSil Medical

OncoSil Medical is a global medical device company focused on Interventional Oncology.

---


Our mission is to improve outcomes by utilising targeted intratumoural placement of  $^{32}\text{P}$  (Phosphorous-32) Microparticles in addition to chemotherapy.

---

OncoSil Medical's lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States.<sup>1</sup>

---

We believe in our technology and its ability to have a truly positive impact in Oncology.



# Experienced Board and Management

## Depth in Interventional Oncology and Nuclear Medicine Commercialisation



**Dr Thomas Duthy**  
Non-executive  
Chairman

20+ years of experience across financial markets, corporate development and board-level roles, involved in numerous successful M&A transactions.



**Nigel Lange**  
Managing Director  
& CEO  
Executive Director

30+ years' experience in medical device industry. Served as Group COO and Interim Group CEO of Sirtex Medical (ASX:SRX).



**Lel Smits**  
Non-executive  
Director

Award-winning entrepreneur, director and investor relations advisor, serving as a Director on Australian Shareholders' Association since 2021.



**Shelley Steyn**  
Chief Financial  
Officer

Extensive experience in senior accounting, commercial and financial analysis, and audit roles across listed and private companies.



**Dr Jon Bell MD**  
Chief Medical  
Officer


12 years' experience as consultant interventional radiologist and an internationally recognised expert in interventional oncology.



**Renzo DiCarlo**  
Head of  
Transformation

A proven nuclear medicine executive Renzo brings over 25 years' experience in therapeutic drugs and medical devices.

# • Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years<sup>1</sup>



## Survival rates are very poor:

- 8.5 months overall median survival
- <12% reach 5-year survival<sup>2</sup>
- Lower survival rate than any other cancer<sup>3</sup>
- The number of cases and deaths both estimated to increase by 40% before 2035<sup>3</sup>




**New therapeutic options urgently needed**

**References:** 1. Cancer Research UK. [www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three](http://www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three) (accessed September 2024).  
 2. American Cancer Society. Cancer Facts & Figures 2023. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf>.  
 3. United European Gastroenterology. Pancreatic Cancer Across Europe: Taking a united stand. <https://ueg.eu/files/771/b7ee6f5f9aa5cd17ca1aea43ce848496.pdf>.

# • Pancreatic Cancer Stage at Diagnosis

**Surgical resection** remains the only potentially curative treatment for pancreatic cancer<sup>1</sup>




**Abbreviations:** CT: Chemotherapy; ICT: Induction chemotherapy; CCRT: Concurrent chemoradiation therapy.

**References:** **1.** Ducreux M et al. Ann Oncol 2015; 26 (Suppl 5): v56-68. **2.** van Dam JL et al. Eur J Cancer. 2022; 160: 140-149. **3.** Chang JS et al. Cancer Res Treat 2018; 50: 562-574 (suppl data). **4.** Burris HA 3rd et al. J Clin Oncol 1997; 15: 2403-2413. **5.** Von Hoff DD et al. N Engl J Med 2013; 369: 1691-1703. **6.** Conroy T et al. N Engl J Med 2011; 364: 1817-1825. **7.** Balaban EP et al. J Clin Oncol 2016; 34: 2654-2668. **8.** National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020. **9.** Huguot et al. J Clin Oncol 2010. **10.** Mukherjee et al, Lancet Oncol 2013.

## Driving increased resection rates, downstaging, survival benefits and quality of life

OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer**, in addition to gemcitabine-based chemotherapy (*combination with FOLFIRINOX currently in trials*)

OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent



**Requires only one supervised procedure given simplicity and familiarity with standard, everyday, biopsy procedures**

OncoSil™ is currently implanted directly into a pancreatic tumour via injection under **endoscopic ultrasound** guidance

**98%** of all radiation is delivered within **81 days** of injection causing damage to cancer cell DNA and **killing malignant cancer cells with no damage to surrounding tissue**



**Percutaneous delivery is transformational and anticipated to significantly accelerate market penetration:**

- ✓ Expanding the number of treating clinicians to include Interventional Radiologists
- ✓ Broader patient access and points of care
- ✓ Outpatient day procedure – complete within 20 minutes
- ✓ Conscious sedation (patient awake)

Patient recruitment at PANCOSIL study completed and preliminary data presented at CIRSE 2025 Congress

**Targeting H2 CY26 to make OncoSil™ commercially available to Interventional Radiologists**

# • Growing Body of Evidence

## 4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC

Study	Unresectable Locally Advanced Pancreatic Cancer (LAPC)				Unresectable LAPC or Borderline-Resectable LAPC		Metastatic PDAC
	PanCO Study <sup>1</sup>	OncoPaC-1 Study <sup>2</sup>	Propensity Score Weighted Landmark Analysis <sup>3</sup>		Comparative Analysis <sup>4</sup>		Metastatic Study <sup>5</sup>
Treatment	OncoSil™ + Chemotherapy <sup>a</sup>	OncoSil™ + gemcitabine/nab-paclitaxel	OncoSil™ + Chemotherapy <sup>b</sup>	vs. Chemotherapy <sup>b</sup> (± Chemoradiotherapy)	OncoSil™ + Chemotherapy <sup>b</sup>	vs. Chemotherapy <sup>b</sup> + SBRT	OncoSil™ + Chemotherapy <sup>a</sup>
Sample Size	42 (50 ITT)	9	50 35 at landmark	54 51 at landmark	42	59	14
Local Disease Control Rate at 16 weeks	90.5%	77.8%	nr	nr	nr	nr	100%
Objective Response Rate	31.0%	22.2%	nr	nr	nr	nr	57.1%
Disease Control Rate	100%	100%	nr	nr	nr	nr	100%
Surgical Resection with Curative Intent	23.8%	0	28.6%	p=0.03 12.1%	22%	p<0.001 0%	7.1%
Downstaging	33.3%	not reported	31.4%	p=0.03 13.6%	23.8%	p=0.003 3.4%	7.1%
Local PFS, median	9.8 months	27.3 months	15.6 months	p=0.006 9.3 months	18.9 months	HR 0.62 p=0.040 14.1 months	12.2 months
Distant PFS or PFS <sup>(PFS)</sup> , median	9.3 months <sup>PFS</sup>	12.2 months <sup>PFS</sup>	14.2 months	p=0.058 10.7 months	20.0 months	HR 0.59 p=0.023 14.0 months	9.2 months <sup>PFS</sup>
Overall Survival, median	15.5 months	27.3 months	20.0 months	p=0.002 12.3 months	22 months	HR 0.45 p=0.014 14 months	13.8 months

**Key:** <sup>a</sup> Gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy; <sup>b</sup> gemcitabine/nab-paclitaxel, gemcitabine or FOLFIRINOX chemotherapy; **Abbreviations:** LAPC, locally advanced pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma; PFS, progression-free survival. Use of OncoSil™ for borderline-resectable LAPC or metastatic pancreatic ductal adenocarcinoma (mPDAC) is off-label.

**References:** 1. Ross PJ et al. Results of a single-arm pilot study of <sup>32</sup>P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/ nab-paclitaxel or FOLFIRINOX chemotherapy. *ESMO Open* February 2022; 7 (1): 100356. 2. OncoSil Medical Ltd. Data on file. 3. Lim A et al. Combined phosphorus-32 implantation and chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis. *Gastrointest Endosc* 2025 May 8. 4. Lim A et al. Comparison of combined chemotherapy and stereotactic body radiation therapy with combined chemotherapy and phosphorus-32 microparticle intra-tumoural implantation in patients with locally advanced pancreatic adenocarcinoma. Presented at Digestive Disease Week (DDW2025) scientific meeting in San Diego, USA, 3–6 May 2025. 5. Lim A et al. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma. *iGIE* 2024 July 2; ePub 1–9.

## Commercialising targeted radiotherapy for pancreatic cancer

- OncoSil Medical is commercialising the OncoSil™ device, an implanted device (brachytherapy) delivering targeted radiation (<sup>32</sup>P) to pancreatic tumours
- OncoSil™ device is now **approved for sale in over 34 countries** via CE Mark
- **Commercial ramp-up** has commenced in FY26, driven by significant growth in existing European markets
- **Increasing market access** via label expansion combining new delivery methods and new chemotherapy combinations<sup>1</sup>
- **Platform technology** can be leveraged into other cancer indications (Bile duct cancer, liver, glioblastoma)
- Experienced Board & Management team in the commercialisation of interventional oncology devices

## >US\$4.2bn global addressable market with no competition<sup>3</sup>

- Granted **Breakthrough designation** in the EU, UK and US with extensive **patent coverage** across all key geographies
- Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the **market expected to increase by 37% by 2035**<sup>2</sup>
- Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months Median Overall
- Patient recruitment completed for **PANCOSIL & TRIPP-FFX** trials, targeting:
  - ✓ **Percutaneous** delivery to drive market access and clinical adoption globally
  - ✓ Label expansion in addition to standard-of-care chemotherapy (**FOLFIRINOX**)

## Significant achievements over CY25

- Received **MDR Approval** which includes the removal of all existing post-market restrictions (OSPREY registry)
- Patient recruitment completed for **PANCOSIL** study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking delivery method for OncoSil™ device)
- Patient recruitment completed for **TRIPP-FFX** trial (to expand OncoSil™ device label with additional chemotherapy combination)
- Second manufacturing facility in **Sydney**, Australia activated and ready to undergo validation.
- Constructive discussions with US **FDA** on the regulatory pathway for OncoSil™ device in Bile Duct Cancer (dCCA)
- German Federal Joint Committee (**G-BA**) tender process underway to appoint a CRO
- First patient treatments completed at **Germany** and **Portugal**

## Catalyst rich CY25/26

- Strong **commercial momentum** and **growing hospital adoption** across existing markets: Austria, Germany, Greece, Israel, Italy, Portugal, Spain, Turkey, and the UK
- **Tender finalisations** expected to drive significant revenue growth
- Finalisation of **G-BA** tender process to appoint CRO and commence recruitment for the G-BA trial
- Label expansion targeting:
  - **Percutaneous delivery** for Interventional Radiology (PANCOSIL study)
  - Combination with standard-of-care chemotherapy - **FOLFIRINOX** (TRIPP-FFX study)
- First commercial production at **Sydney** manufacturing facility (H1 CY26)
- **Publication of real-world clinical data** to support market access and drive adoption
- Accelerating commercial activities through expanded market access and new geographic opportunities across the **Nordics** and **MENA** regions<sup>1</sup>
- TGA Approval – in review

# Significant Commercial Opportunity

## Existing Priority Markets

Target Market	Pancreatic Cancer Incidence p.a. <sup>1</sup>	Locally Advanced Pancreatic Cancer <sup>2</sup>	Market Opportunity (A\$m) <sup>3</sup>
UK	11,852	3,556	138
Spain	9,282	2,785	108
Italy	16,111	4,833	188
Germany	22,587	6,776	264
Greece	2,343	703	27
Austria	2,250	675	26
Turkiye	9,012	2,704	105
Portugal	2,217	665	26
Israel	1,249	375	15
<b>Total (Existing)</b>	<b>76,903</b>	<b>23,071</b>	<b>898</b>

## Near-Term Target Markets

South Korea	10,046	3,014	117
France	16,538	4,961	193
Denmark	1,454	436	17
Finland	1,570	471	18
Norway	1,275	383	15
Switzerland	2,056	617	24
Saudi Arabia	666	200	8
Hong Kong	1,116	335	13
Netherlands	3,689	1,107	43
Belgium	2,433	730	28
<b>Total (New)</b>	<b>40,843</b>	<b>12,253</b>	<b>477</b>



OncoSil™ device remains **at the early-stage of commercialization** in existing geographies with ~A\$898m market size


Expanding to ~A\$1,375m addressable market over next **18 - 24 months**

Market Penetration expected to now accelerate over the near-term driven by:

- Percutaneous Delivery following a target H2 CY26 label expansion
- Commencement of Patient Recruitment for the G-BA Trial

# Upcoming Milestones

## Significant catalysts over the next 12 months





## Nigel Lange

CEO & Managing Director

E: [nigel.lange@oncosil.com](mailto:nigel.lange@oncosil.com)

### Learn more about OncoSil Medical:

- [Website](#)
- [ASX announcements](#)
- [LinkedIn](#)

Targeted Approach • Positive Impact

